Cyclerion Therapeutics
CYCN
70 hedge funds and large institutions have $62.4M invested in Cyclerion Therapeutics in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 10 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 16
0.07% more ownership
Funds ownership: 3.22% → 3.29% (+0.07%)
4% less funds holding
Funds holding: 73 → 70 (-3)
7% less capital invested
Capital invested by funds: $66.9M → $62.4M (-$4.45M)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
41% less call options, than puts
Call options by funds: $59K | Put options by funds: $100K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.13M |
| 2 |
Renaissance Technologies
New York
|
+$809K |
| 3 |
Two Sigma Advisers
New York
|
+$425K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$373K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$351K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.41M |
| 2 |
New York State Common Retirement Fund
Albany,
New York
|
-$457K |
| 3 |
D.E. Shaw & Co
New York
|
-$424K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$191K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$160K |
CYCN Hedge Fund Activity: Q1 2021 in Review
70 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q1 2021, worth a combined $62.4M — down 6.7% from $66.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CYCN and 7 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 27 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.13M. The largest seller was Morgan Stanley, cutting an estimated $1.41M.
- 70 institutional investors held Cyclerion Therapeutics (CYCN) as of Q1 2021, down from 73 in Q4 2020.
- Funds reported $62.4M of Cyclerion Therapeutics stock for Q1 2021, down 6.7% quarter-over-quarter.
- 7 funds opened new Cyclerion Therapeutics positions in Q1 2021 and 10 closed out, a net change of -3 holders.
- The largest Cyclerion Therapeutics buyer in Q1 2021 was Ikarian Capital, an estimated $1.13M added.
- The largest Cyclerion Therapeutics seller in Q1 2021 was Morgan Stanley, an estimated $1.41M sold.
Based on aggregated 13F filings for Q1 2021.